CN-121588108-B - Medicament for treating SLE, active ingredient and application

Abstract

The invention belongs to the field of medicines, and in particular relates to a medicine for treating SLE, an active ingredient and application thereof, wherein the active ingredient for treating SLE comprises an active ingredient A and an active ingredient B, wherein the active ingredient A is shown in the formula 1% ) The active component B is shown in the formula 2 ) A compound. Innovative researches of the invention show that the combination of the formula 1 and the formula 2 can realize synergistic effect and can effectively improve the treatment effect of SLE. The active ingredient disclosed by the invention can effectively inhibit the proliferation of B cells, regulate and control histone modification, effectively improve the phenotype result of lupus model mice, and provide a new way for the mechanism exploration and drug research and development of lupus erythematosus diseases.

Inventors

• WU HAIJING
• TAN YIXIN
• ZHOU SUQING
• LU QIANJIN
• CHEN HUI
• YANG MING
• YIN HUAN
• LI ZHAOXIANG
• Ji Fanghan
• LI YAPING

Assignees

• 中南大学湘雅二医院

Dates

Publication Date

20260512

Application Date

20260128

Claims (8)

1. 1. An active ingredient for treating SLE, comprising an active ingredient a and an active ingredient B; Wherein the active ingredient A is a compound of formula 1, and the active ingredient B is a compound of formula 2; Formula 1; Formula 2; the content of the active ingredient A is more than 10 wt.%; The concentration ratio of formula 1 to formula 2 in the active ingredient is 1:1, or the dosage of formula 2 is 10 mg/kg, and the dosage of formula 1 is 2 mg/kg.
2. 2. Use of an active ingredient according to claim 1 for the preparation of a medicament for the treatment of SLE.
3. 3. The use of an active ingredient according to claim 2 for the preparation of a medicament for the treatment of SLE, wherein the active ingredient is combined with pharmaceutically acceptable excipients for the preparation of a medicament for the treatment of SLE.
4. 4. Use of an active ingredient according to claim 2 or 3 in the manufacture of a medicament for the treatment of SLE, in a pharmaceutically acceptable dosage form.
5. 5. A medicament for the treatment of SLE, characterized in that it comprises a pharmaceutically effective amount of an active ingredient according to claim 1.
6. 6. The medicament for treating SLE as recited in claim 5, comprising pharmaceutically acceptable excipients.
7. 7. The medicament for treating SLE as recited in claim 6, wherein said medicament is in a pharmaceutically acceptable dosage form.
8. 8. The medicament for treating SLE as claimed in claim 7, which is an oral preparation, an injectable preparation or an external preparation.

Description

Medicament for treating SLE, active ingredient and application Technical Field The invention relates to the technical field of medicines, in particular to the fields of medicines, active ingredients and application for treating SLE. Background Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can involve multiple organ systems such as the kidneys, joints, etc. The existing SLE treatment still lacks ideal schemes, the diseases are easy to relapse and difficult to radically cure, and the diagnosis and treatment of SLE are extremely challenging. Autoantibodies form immune complexes with antigens and deposit in multiple organs, thereby triggering autoimmune reactions, which are the core mechanism for SLE development. The immune abnormal activation of pathogenic B cells is being studied deeply, helping to elucidate the pathogenesis of the disease. Of particular interest are the characteristic and reversible changes in antibody secreting B cells at the epigenetic level, or potential breakthrough points for SLE diagnosis and treatment. At present, the main therapeutic ideas for SLE focus on suppressing abnormal immune response, reducing inflammatory injury, controlling disease activity and the like. Methods of treatment encompass drug therapy, immunomodulation therapy, emerging biological therapies, and the like. In the aspect of drug treatment, non-steroidal anti-inflammatory drugs, antimalarial drugs, glucocorticoids, immunosuppressants, chinese patent medicines and the like are often used to relieve symptoms and control the progress of the disease. Immunomodulatory therapy restores immune balance by modulating the function of the immune system. The prior art discloses methods for treating SLE, for example, patent document publication No. CN120983413a discloses the use of docosapentaenoic acid or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and/or treating systemic lupus erythematosus. The chinese patent publication No. CN120718909a discloses a neutralizing aptamer targeted to inhibit B cell activating factor and its use in systemic lupus erythematosus treatment. The patent document with publication number CN120884651A discloses a traditional Chinese medicine composition for preventing/treating systemic lupus erythematosus and application thereof, wherein the traditional Chinese medicine composition comprises the components of pseudo-ginseng, glossy privet fruit, sea dragon, red sage root, safflower, peach seed, american ginseng, radix codonopsitis, prepared rhizome of rehmannia, medlar, mulberry, bamboo joint, hairy antler, epimedium herb, sea horse, dried orange peel, tuber fleeceflower root, angelica, white paeony root, sealwort, dog kidney and the like. For another example, patent document publication No. CN120210130a discloses an E-CAR-NK cell for treating systemic lupus erythematosus and uses thereof. In summary, although the prior art discloses more methods of treating SLE, the means of treatment remain to be further extended. Disclosure of Invention In view of the shortcomings of the prior art, the present invention aims to provide an active ingredient for treating SLE, and aims to provide an active ingredient with high activity and safety capable of effectively treating SLE. A second object of the present invention is to provide the use of said active principle in the preparation of a medicament for the treatment of SLE. A third object of the present invention is to provide a medicament for the treatment of SLE comprising said active ingredient. An active ingredient for the treatment of SLE comprising an active ingredient a and an active ingredient B; Wherein the active ingredient A is a compound of formula 1 (also referred to as formula one in the invention), and the active ingredient B is a compound of formula 2 (also referred to as formula two in the invention); Formula 1; Formula 2. Innovative researches of the invention show that the combination of the formula 1 and the formula 2 can realize synergy and can effectively improve the treatment effect of SLE. The active ingredient disclosed by the invention can effectively inhibit B cell differentiation and antibody secretion, effectively improve the phenotype result of lupus, and provide a new way for the mechanism exploration and drug research and drug development of lupus erythematosus diseases. The active ingredient A and the active ingredient B can be free compounds with respective chemical structures and crystals or salts thereof. For example, the active ingredient a may be the hydrochloride salt of formula 1. In the present invention, the content of the active ingredient in formula 1 is 10wt.% or more, and may be 10 to 50wt.%. The invention also provides an application of the active ingredient in preparing a medicament for treating SLE. The application of the invention combines the active ingredients with pharmaceutically acceptable auxiliary materials to prepare the medicine for tre